Drug Delivery Platform
polymer physics, biophysics
responses generated
Lavoisier Polymer Nanoencapsulation Platform
Lavoisier’s proprietary polymer nanoencapsulation platform is aimed to address a variety of challenges in the commercialization of biopharmaceuticals, such as therapeutic enzymes, vaccines, and monoclonal antibodies. Endeavors and achievements of applying the Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Polymer Nanoencapsulation Platform
Polymer nanoparticles encapsulation drug provides the benefit of bioavailability, pharmacokinetic issues, and drug distribution, reduced toxicity of the drug. However, polymer nanoparticles encapsulation drug delivery still holds some challenges that low penetration and fragility of large molecules.
Lavoisier Polymer Nanoencapsulation Platform
Endeavors and achievements of applying Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Lavoisier Research and Design
Lavoisier has revisited the philosophy of polymer physics, biophysics, and polymer chemistry and creatively combined the knowledge in these scientific disciplines to address the barriers associated the conventional wisdom of designing nanoencapsulation. We provide a revolutionary solution to the problems.
Advancing novel approach to reduce/enhance/adjust immunogenicity
With our in-vivo validated encapsulation platform, we intend to apply Lavoisier encapsulation platform to a series of selected biotherapeutics for treating various diseases. A near term goal is to develop a biopharmaceutical, which is encapsulated by Lavoisier platform, to satisfy the urgent need of treating COVID-19.
Advancing novel encapsulated biopharmaceuticals
With our in-vivo validated encapsulation platform, we are testing the ability of Lavoisier platform in reducing/enhancing/fine-tuning immunogenicity of biopharmaceuticals of interest based on the needs of specific treatments.
Controlled, scalable Process
Formulations of Lavoisier nanoencapsulation are produced in processes that fully comply with Good Manufacturing Practice (GMP).Proprietary polymer as excipient is suitable for production at a commercial scale via a well-controlled and scalable manufacturing polymer process.